Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452710 · ClinicalTrials.gov registry record · NA
Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02452710 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT02452710, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This research study is evaluating the usefulness of a placebo (a tablet with no active ingredients) on fatigue in cancer survivors.
Interventions
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452710
The ClinicalTrials.gov registry entry for NCT02452710 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Placebo is the first listed.
NCT02452710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452710 about?
NCT02452710 is a clinical study titled "Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors". This research study is evaluating the usefulness of a placebo (a tablet with no active ingredients) on fatigue in cancer survivors.
What is the current status of trial NCT02452710?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2015-08. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02452710?
The interventions under investigation include: Placebo (OTHER).
Who is sponsoring clinical trial NCT02452710?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.